DrugPatentWatch Database Preview
NUZYRA Drug Profile
When do Nuzyra patents expire, and when can generic versions of Nuzyra launch?
Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. There are two patents protecting this drug.
This drug has twelve patent family members in eleven countries.
The generic ingredient in NUZYRA is omadacycline tosylate. One supplier is listed for this compound. Additional details are available on the omadacycline tosylate profile page.
Summary for NUZYRA
| International Patents: | 12 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | NUZYRA at DailyMed |
Generic Entry Opportunity Date for NUZYRA
Generic Entry Dates for NUZYRA*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW NDA:
Dosage:
POWDER;INTRAVENOUS |
Generic Entry Dates for NUZYRA*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for NUZYRA
International Patents for NUZYRA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201808307 | ➤ Try a Free Trial |
| Mexico | 2010009693 | ➤ Try a Free Trial |
| European Patent Office | 2262754 | ➤ Try a Free Trial |
| Russian Federation | 2010140682 | ➤ Try a Free Trial |
| Canada | 2717703 | ➤ Try a Free Trial |
| China | 102015602 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
